Haier Biomedical Posts Record Overseas Growth as AI Revenue Climbs to 15% of Sales
Haier Biomedical reported 2.33 billion yuan (USD 340.77 million) in full-year 2025 revenue, with overseas sales reaching 840 million yuan-a 17.9% increase and now 36% of total revenue. The Shanghai-listed life sciences company achieved double-digit growth across all four international regions despite a volatile trade environment.
The shift from product exports to branded global operations marks a strategic inflection point. Asia-Pacific revenue grew 26%, while Europe expanded 16%. The company now operates subsidiaries in four countries and localized operations in 18 others.
AI-Driven Solutions Drive Revenue Mix
AI-related revenue reached 15% of total sales, up 2.5 percentage points year-over-year. The company built what it calls a "multi-layer AI infrastructure" comprising large models, AI agents, and AI terminals, with 17 proprietary agents integrated into 13 automated solutions.
AI-powered automated pharmacies achieved 80% direct dispensing rates-1.1 times the industry average. A fully automated cell workstation won China's Ministry of Industry and Information Technology award for disruptive technology. The company's fully closed automated cell expansion system entered clinical trials for bioartificial liver applications.
New business segments-smart medication, blood technology, and laboratory solutions-contributed 48.5% of revenue, up 8.8% year-over-year.
Three-Year Targets Signal Aggressive Expansion
Haier Biomedical outlined a "543" strategic plan for the next three years:
- Overseas revenue to exceed 50% of total sales through localized operations
- Acquired businesses to contribute at least 40% of future revenue via platform-based external growth
- AI-related revenue to account for over 30% of total sales
The company invested 320 million yuan (USD 46.82 million) in R&D during 2025, filing 1,620 new invention patents-a 50% increase. Eleven solutions achieved industry-first status, including the company's mastery of stable 100,000-rpm ultra-high-speed centrifugation technology.
Regulatory Wins and Market Position
Haier Biomedical's plasma separation system became the first Chinese solution to receive EU Medical Device Regulation certification. Its ultra-low temperature biomedical freezers hold the top eight positions in the ENERGY STAR program.
The company holds over 400 international product certifications and partners with nearly 80 international organizations, including the World Health Organization and UNICEF. Its distribution network spans more than 800 partners across 160 countries and regions.
Ultra-low and low-temperature biomedical freezers ranked first in market share in six countries, including Italy. The company also leads domestic peers in export volume of smart medication dispensing solutions.
For executives tracking AI adoption in industrial applications, Haier Biomedical's strategy offers a case study in how large enterprises embed AI across product lines while pursuing geographic expansion. The company's three-year targets-particularly the 30% AI revenue goal-signal how AI is shifting from a competitive advantage to a baseline requirement in life sciences equipment.
Learn more about AI for Executives & Strategy and Generative AI and LLM applications in enterprise settings.
Your membership also unlocks:
